3-indazolinone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 81829 |
| CHEMBL ID | 276725 |
| SCHEMBL ID | 276725 |
| SCHEMBL ID | 1068870 |
| SCHEMBL ID | 16178927 |
| MeSH ID | M0123075 |
| Synonym |
|---|
| unii-8e254s9s1r |
| 8e254s9s1r , |
| 3h-indazol-3-one,2-dihydro- |
| nsc-9352 |
| 3-indazolinone |
| 1h-indazol-3-ol |
| 3-oxo-1,2-indazole |
| 3-hydroxy-1h-indazole |
| 7364-25-2 |
| 1,2-dihydro-3h-indazol-3-one |
| nsc9352 |
| indazolinone |
| benzopyrazol-3- |
| 1,2-dihydroindazol-3-one |
| 1,2-dihydro-1h-indazol-3-one |
| 3-indazolinone, 97% |
| EC-000.1563 |
| nsc 9352 |
| 3h-indazol-3-one, 1,2-dihydro- |
| 3-indazolone |
| ccris 6800 |
| einecs 230-904-2 |
| CHEMBL276725 , |
| sweicgmkxpnxnu-uhfffaoysa- |
| inchi=1/c7h6n2o/c10-7-5-3-1-2-4-6(5)8-9-7/h1-4h,(h2,8,9,10) |
| 1,2-dihydro-indazol-3-one |
| bdbm50008990 |
| A837883 |
| 3-indazolinone;3-oxo-2,3-dihydro-1h-indazole |
| AKOS009157211 |
| 3-HYDROXYINDAZOLE , |
| EN300-49155 |
| dtxcid1029388 |
| dtxsid2049428 , |
| tox21_202943 |
| cas-7364-25-2 |
| NCGC00260489-01 |
| AKOS015919423 |
| 100922-96-1 |
| 2,3-dihydro-1h-indazol-3-one |
| FT-0615868 |
| S10203 |
| 1h-indazol-3(2h)-one |
| SCHEMBL276725 |
| hydroxyindazole |
| SCHEMBL1068870 |
| I0929 |
| SCHEMBL16178927 |
| 70010-33-2 |
| mfcd00005685 |
| 2h-indazol-3-ol |
| C71048 |
| CS-W013384 |
| DS-5508 |
| mfcd00044658 |
| Q27270248 |
| A897296 |
| SY051085 |
| CS-0166826 |
| PD179171 |
| SY325041 |
| mfcd00234274 |
| Z586248764 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 15.6368 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521 |
| AR protein | Homo sapiens (human) | Potency | 23.5752 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID743035; AID743036; AID743063 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 52.4647 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 62.8233 | 0.0002 | 14.3764 | 60.0339 | AID720692 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 36.8054 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 14.0644 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 62.2513 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 49.9023 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 62.2513 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 49.9023 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 115.9765 | 0.0391 | 47.5451 | 146.8240 | AID1224845; AID1224896 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 62.2513 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 62.2513 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Polyunsaturated fatty acid 5-lipoxygenase | Rattus norvegicus (Norway rat) | IC50 (µMol) | 2.0000 | 0.0046 | 2.0182 | 10.0000 | AID179757 |
| Cytochrome P450 11B1, mitochondrial | Rattus norvegicus (Norway rat) | IC50 (µMol) | 30.0000 | 0.4950 | 3.5289 | 5.0000 | AID179759 |
| Sodium- and chloride-dependent GABA transporter 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 30.0000 | 0.0013 | 2.2206 | 8.3000 | AID179759 |
| Nitric oxide synthase, brain | Homo sapiens (human) | IC50 (µMol) | 1,000.0000 | 0.0350 | 2.7119 | 10.0000 | AID449906 |
| Nitric oxide synthase, brain | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1,000.0000 | 0.0400 | 4.1638 | 9.3000 | AID589268 |
| Sodium- and chloride-dependent GABA transporter 2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 30.0000 | 0.0032 | 1.7900 | 8.3000 | AID179759 |
| Sodium- and chloride-dependent GABA transporter 3 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 30.0000 | 0.0032 | 1.5431 | 8.3000 | AID179759 |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 30.0000 | 0.0029 | 1.7868 | 10.0000 | AID179759 |
| Sodium- and chloride-dependent betaine transporter | Rattus norvegicus (Norway rat) | IC50 (µMol) | 30.0000 | 0.0032 | 1.5431 | 8.3000 | AID179759 |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 30.0000 | 0.0029 | 1.8232 | 10.0000 | AID179759 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| D-amino-acid oxidase | Sus scrofa (pig) | Kd | 4.4300 | 0.1500 | 2.8100 | 6.3000 | AID1389535 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID179757 | In vitro inhibition of LTB4 production was measured in rat blood | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. |
| AID59291 | In vitro test for the induction of the production of methemoglobin (MHb) in dog blood | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. |
| AID128761 | Reduction of serum cholesterol in CF1 male mice on day 16 following 20 mg/kg/day i.p. administration. | 1984 | Journal of medicinal chemistry, Jun, Volume: 27, Issue:6 | Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogues. |
| AID128763 | Reduction of serum triglycerides in CF1 male mice on day 16 following 20 mg/kg/day i.p. administration. | 1984 | Journal of medicinal chemistry, Jun, Volume: 27, Issue:6 | Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogues. |
| AID589268 | Inhibition of nNOS in LPS-stimulated Wistar rat striata assessed as inhibition of [3H]L-arginine to [3H]L-citrulline conversion by liquid scintillation counting | 2011 | European journal of medicinal chemistry, Apr, Volume: 46, Issue:4 | Synthesis and biological evaluation of indazole derivatives. |
| AID589266 | Inhibition of iNOS in LPS-stimulated Wistar rat lung assessed as inhibition of [3H]L-arginine to [3H]L-citrulline conversion at 1 mM by liquid scintillation counting | 2011 | European journal of medicinal chemistry, Apr, Volume: 46, Issue:4 | Synthesis and biological evaluation of indazole derivatives. |
| AID1389535 | Binding affinity to pig kidney DAAO by ITC method | 2018 | Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8 | Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors. |
| AID128762 | Reduction of serum cholesterol in CF1 male mice on day 9 following 20 mg/kg/day i.p. administration. | 1984 | Journal of medicinal chemistry, Jun, Volume: 27, Issue:6 | Hypolipidemic activity of phthalimide derivatives. 7. Structure-activity studies of indazolone analogues. |
| AID179759 | In vitro inhibition of PGE-2 production was measured in rat blood | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. |
| AID101296 | In vitro inhibition of LTB4 (LT) production in dog blood | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. |
| AID1389534 | Dissociation constant, pKa of the compound by UV-spectrophotometric titration method | 2018 | Bioorganic & medicinal chemistry, 05-01, Volume: 26, Issue:8 | Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors. |
| AID449906 | Inhibition of recombinant NOS1 assessed as citrulline formation | 2009 | Bioorganic & medicinal chemistry, Sep-01, Volume: 17, Issue:17 | Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): synthesis and biological evaluation. |
| AID101295 | Ex vivo inhibition of LTB4 production was measured in dog blood | 1991 | Journal of medicinal chemistry, Mar, Volume: 34, Issue:3 | Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity. |
| AID589267 | Inhibition of nNOS in LPS-stimulated Wistar rat striata assessed as inhibition of [3H]L-arginine to [3H]L-citrulline conversion at 1 mM by liquid scintillation counting | 2011 | European journal of medicinal chemistry, Apr, Volume: 46, Issue:4 | Synthesis and biological evaluation of indazole derivatives. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.04) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||